Daridorexant for insomnia disorder

Affiliations

¹ Department of Psychiatry and Psychotherapy, Faculty of Medicine, Medical Center-University of Freiburg, University of Freiburg, 79104 Freiburg, Germany. Electronic address: kai.spiegelhalder@uniklinik-freiburg.de.
² Department of Psychiatry and Psychotherapy, Faculty of Medicine, Medical Center-University of Freiburg, University of Freiburg, 79104 Freiburg, Germany.
³ Sir Jules Thorn Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.

Comment

Kai Spiegelhalder et al. Lancet Neurol. 2022 Feb.

. 2022 Feb;21(2):104-105.

doi: 10.1016/S1474-4422(22)00007-2.

¹ Department of Psychiatry and Psychotherapy, Faculty of Medicine, Medical Center-University of Freiburg, University of Freiburg, 79104 Freiburg, Germany. Electronic address: kai.spiegelhalder@uniklinik-freiburg.de.
² Department of Psychiatry and Psychotherapy, Faculty of Medicine, Medical Center-University of Freiburg, University of Freiburg, 79104 Freiburg, Germany.
³ Sir Jules Thorn Sleep and Circadian Neuroscience Institute, Nuffield Department of Clinical Neuroscience, University of Oxford, Oxford, UK.

No abstract available

Conflict of interest statement

We declare no competing interests.

Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials.
Mignot E, Mayleben D, Fietze I, Leger D, Zammit G, Bassetti CLA, Pain S, Kinter DS, Roth T; investigators. Mignot E, et al. Lancet Neurol. 2022 Feb;21(2):125-139. doi: 10.1016/S1474-4422(21)00436-1. Lancet Neurol. 2022. PMID: 35065036 Clinical Trial.